PAC1 deficiency attenuates progression of atherosclerosis in ApoE deficient mice under cholesterol-enriched diet. 2020

Paul Splitthoff, and Erik Rasbach, and Philip Neudert, and Gabriel A Bonaterra, and Anja Schwarz, and Lilli Mey, and Hans Schwarzbach, and Lee E Eiden, and Eberhard Weihe, and Ralf Kinscherf
Department of Medical Cell Biology, Institute for Anatomy and Cell Biology, Medical Faculty, Philipps-University of Marburg, Robert-Koch-Str. 8, 35037, Marburg, Germany.

The neuropeptide, pituitary adenylate cyclase-activating polypeptide (PACAP) is vasoactive and cytoprotective and exerts immunoregulatory functions throughout the nervous, neuroendocrine cardiovascular and immune systems in health and disease. PACAP mainly acts through PAC1 receptor signaling in neuronal communication, but the role of PAC1 in immune regulation of atherosclerosis is not known. Here, we generated PAC1-/-/ApoE-/- mice to test, whether PAC1-/- influences plasma cholesterol-/triglyceride levels and/or atherogenesis in the brachiocephalic trunk (BT) seen in ApoE-/- mice, under standard chow (SC) or cholesterol-enriched diet (CED). Furthermore, the effect of PAC1-/-, on inflammatory, autophagy-, apoptosis- and necroptosis-relevant proteins in atherosclerotic plaques was determined. In plaques of PAC1-/-/ApoE-/- mice fed a SC, the immunoreactivity for apoptotic, autophagic, necroptotic and proinflammatory proteins was increased, however, proliferation was unaffected. Interestingly, without affecting hyperlipidemia, PAC1-/- in ApoE-/- mice remarkably reduced CED-induced lumen stenosis seen in ApoE-/- mice. Thus, PAC1-/- allows unchecked inflammation, necroptosis and decreased proliferation during SC, apparently priming the BT to develop reduced atheroma under subsequent CED. Remarkably, no differences in inflammation/necroptosis signatures in the atheroma under CED between PAC1-/-/ApoE-/- and ApoE-/- mice were observed. These data indicate that selective PAC1 antagonists should offer potential as a novel class of atheroprotective therapeutics, especially during hypercholesterolemia.

UI MeSH Term Description Entries
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D002791 Cholesterol, Dietary Cholesterol present in food, especially in animal products. Dietary Cholesterol
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004198 Disease Susceptibility A constitution or condition of the body which makes the tissues react in special ways to certain extrinsic stimuli and thus tends to make the individual more than usually susceptible to certain diseases. Diathesis,Susceptibility, Disease,Diatheses,Disease Susceptibilities,Susceptibilities, Disease
D006720 Homozygote An individual in which both alleles at a given locus are identical. Homozygotes
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001057 Apolipoproteins E A class of protein components which can be found in several lipoproteins including HIGH-DENSITY LIPOPROTEINS; VERY-LOW-DENSITY LIPOPROTEINS; and CHYLOMICRONS. Synthesized in most organs, Apo E is important in the global transport of lipids and cholesterol throughout the body. Apo E is also a ligand for LDL receptors (RECEPTORS, LDL) that mediates the binding, internalization, and catabolism of lipoprotein particles in cells. There are several allelic isoforms (such as E2, E3, and E4). Deficiency or defects in Apo E are causes of HYPERLIPOPROTEINEMIA TYPE III. Apo-E,Apo E,Apo E Isoproteins,ApoE,Apolipoprotein E Isoproteins,Apoprotein (E),Apoproteins E,Isoproteins, Apo E,Isoproteins, Apolipoprotein E
D001343 Autophagy The segregation and degradation of various cytoplasmic constituents via engulfment by MULTIVESICULAR BODIES; VACUOLES; or AUTOPHAGOSOMES and their digestion by LYSOSOMES. It plays an important role in BIOLOGICAL METAMORPHOSIS and in the removal of bone by OSTEOCLASTS. Defective autophagy is associated with various diseases, including NEURODEGENERATIVE DISEASES and cancer. Autophagocytosis,ER-Phagy,Lipophagy,Nucleophagy,Reticulophagy,Ribophagy,Autophagy, Cellular,Cellular Autophagy,ER Phagy
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

Paul Splitthoff, and Erik Rasbach, and Philip Neudert, and Gabriel A Bonaterra, and Anja Schwarz, and Lilli Mey, and Hans Schwarzbach, and Lee E Eiden, and Eberhard Weihe, and Ralf Kinscherf
January 2008, Atherosclerosis,
Paul Splitthoff, and Erik Rasbach, and Philip Neudert, and Gabriel A Bonaterra, and Anja Schwarz, and Lilli Mey, and Hans Schwarzbach, and Lee E Eiden, and Eberhard Weihe, and Ralf Kinscherf
November 2023, BMC cardiovascular disorders,
Paul Splitthoff, and Erik Rasbach, and Philip Neudert, and Gabriel A Bonaterra, and Anja Schwarz, and Lilli Mey, and Hans Schwarzbach, and Lee E Eiden, and Eberhard Weihe, and Ralf Kinscherf
December 2015, Atherosclerosis,
Paul Splitthoff, and Erik Rasbach, and Philip Neudert, and Gabriel A Bonaterra, and Anja Schwarz, and Lilli Mey, and Hans Schwarzbach, and Lee E Eiden, and Eberhard Weihe, and Ralf Kinscherf
March 2018, Journal of molecular and cellular cardiology,
Paul Splitthoff, and Erik Rasbach, and Philip Neudert, and Gabriel A Bonaterra, and Anja Schwarz, and Lilli Mey, and Hans Schwarzbach, and Lee E Eiden, and Eberhard Weihe, and Ralf Kinscherf
September 2011, Journal of lipid research,
Paul Splitthoff, and Erik Rasbach, and Philip Neudert, and Gabriel A Bonaterra, and Anja Schwarz, and Lilli Mey, and Hans Schwarzbach, and Lee E Eiden, and Eberhard Weihe, and Ralf Kinscherf
January 2022, Drug design, development and therapy,
Paul Splitthoff, and Erik Rasbach, and Philip Neudert, and Gabriel A Bonaterra, and Anja Schwarz, and Lilli Mey, and Hans Schwarzbach, and Lee E Eiden, and Eberhard Weihe, and Ralf Kinscherf
June 2017, Chemico-biological interactions,
Paul Splitthoff, and Erik Rasbach, and Philip Neudert, and Gabriel A Bonaterra, and Anja Schwarz, and Lilli Mey, and Hans Schwarzbach, and Lee E Eiden, and Eberhard Weihe, and Ralf Kinscherf
February 2014, Archives of medical science : AMS,
Paul Splitthoff, and Erik Rasbach, and Philip Neudert, and Gabriel A Bonaterra, and Anja Schwarz, and Lilli Mey, and Hans Schwarzbach, and Lee E Eiden, and Eberhard Weihe, and Ralf Kinscherf
August 2016, Journal of lipid research,
Paul Splitthoff, and Erik Rasbach, and Philip Neudert, and Gabriel A Bonaterra, and Anja Schwarz, and Lilli Mey, and Hans Schwarzbach, and Lee E Eiden, and Eberhard Weihe, and Ralf Kinscherf
January 2014, PloS one,
Copied contents to your clipboard!